Edwards Lifesciences (NYSE:EW) announces CE Mark certification for its SAPIEN 3 transcatheter heart valve for the treatment of patients diagnosed with aortic stenosis who are at low risk for open-heart surgery, the first transcatheter aortic valve implantation (TAVI) system to have this indication in Europe.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.